N
Nilesh Gardi
Researcher at Homi Bhabha National Institute
Publications - 4
Citations - 71
Nilesh Gardi is an academic researcher from Homi Bhabha National Institute. The author has contributed to research in topics: Gallbladder cancer & Gallbladder. The author has an hindex of 3, co-authored 4 publications receiving 36 citations.
Papers
More filters
Journal ArticleDOI
ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer
Prajish Iyer,Shailesh V. Shrikhande,Malika Ranjan,Asim Joshi,Nilesh Gardi,Ratnam Prasad,Bhasker Dharavath,Rahul Thorat,Sameer Salunkhe,Bikram Sahoo,Pratik Chandrani,Hitesh Kore,Bhabani Mohanty,Vikram Chaudhari,Anuradha Choughule,Dhananjay Kawle,Pradip Chaudhari,Arvind Ingle,Shripad Banavali,Poonam Gera,Mukta Ramadwar,Kumar Prabhash,Savio George Barreto,Shilpee Dutt,Amit Dutt +24 more
TL;DR: Overall, besides implicating ERBB2 as an important therapeutic target under neo‐adjuvant or adjuvant settings, this work presents the first evidence that the presence of KRAS mutations may preclude gallbladder cancer patients to respond to anti‐ EGFR treatment, similar to a clinical algorithm commonly practiced to opt for anti‐EGFR treatment in colorectal cancer.
Journal ArticleDOI
Up-regulation of the kinase gene SGK1 by progesterone activates the AP-1–NDRG1 axis in both PR-positive and -negative breast cancer cells
Mukul Godbole,Trupti Togar,Kuldeep J. Patel,Bhasker Dharavath,Neelima Yadav,Sharan Janjuha,Nilesh Gardi,Kanishka Tiwary,Prachi Terwadkar,Sanket Desai,Ratnam Prasad,Hemant Dhamne,Kunal Karve,Sameer Salunkhe,Dhananjay Kawle,Pratik Chandrani,Shilpee Dutt,Sudeep Gupta,Rajendra A. Badwe,Amit Dutt +19 more
TL;DR: A model for the mode of action of progesterone in breast cancer is proposed and it is found that NDRG1, in turn, inactivates a set of kinases, impeding the invasion and migration of breast cancer cells.
Journal ArticleDOI
miR-129-2 mediates down-regulation of progesterone receptor in response to progesterone in breast cancer cells.
Mukul Godbole,Pratik Chandrani,Nilesh Gardi,Hemant Dhamne,Kuldeep J. Patel,Neelima Yadav,Sudeep Gupta,Rajendra A. Badwe,Amit Dutt +8 more
TL;DR: Modulation of activity of miR-129-2 could stabilize PR expression and potentially improve response to hormonal therapy under adjuvant or neo-adjuvant settings and potentiate PR expression levels among patients with inadequate PR levels.
Posted ContentDOI
ERBB2 and KRAS Alterations Mediate Response to EGFR Inhibitors in early stage Gallbladder Cancer
Prajish Iyer,Shailesh V. Shrikhande,Malika Ranjan,Asim Joshi,Ratnam Prasad,Nilesh Gardi,Rahul Thorat,Sameer Salunkhe,Bhasker Dharavath,Bikram Sahoo,Pratik Chandrani,Hitesh Kore,Bhabani Mohanty,Vikram Chaudhari,Anuradha Choughule,Dhananjay Kawle,Pradip Chaudhari,Arvind Ingle,Shripad Banavali,Mukta Ramadwar,Kumar Prabhash,Savio George Barreto,Shilpee Dutt,Amit Dutt +23 more
TL;DR: Recurrent activating ERBB2 and KRAS somatic mutations are present in 6 and 3 of 44 early-stage rare gallbladder tumors, respectively, providing the first evidence that the presence of KRAS (G12V), but not KRas (G13D) mutation, may precludegallbladder cancer patients to respond to anti-EGFR treatment.